RT Journal Article
T1 Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases
A1 Fernández Albarral, José Antonio
A1 Hoz Montañana, María Rosa de
A1 Ramírez Sebastián, Ana Isabel
A1 López Cuenca, Inés
A1 García Martín, Elena Salobrar
A1 Pinazo Durán, Mª Dolores
A1 Ramirez Sebastian, Jose Manuel
A1 Salazar Corral, Juan José
AB Saffron (Crocus sativus L.) has been traditionally used in food preparation and as a medicinal plant. It currently has numerous therapeutic properties attributed to it, such as protection against ischemia, as well as anticonvulsant, antidepressant, anxiolytic, hypolipidemic, anti-atherogenic, anti-hypertensive, antidiabetic, and anti-cancer properties. In addition, saffron has remarkable beneficial properties, such as anti-apoptotic, anti-inflammatory and antioxidant activities, due to its main metabolites, among which crocin and crocetin stand out. Furthermore, increasing evidence underwrites the possible neuroprotective role of the main bioactive saffron constituents in neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases, both in experimental models and in clinical studies in patients. Currently, saffron supplementation is being tested for ocular neurodegenerative pathologies, such as diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration and glaucoma, among others, and shows beneficial effects. The present article provides a comprehensive and up to date report of the investigations on the beneficial effects of saffron extracts on the main neurodegenerative ocular pathologies and other ocular diseases. This review showed that saffron extracts could be considered promising therapeutic agents to help in the treatment of ocular neurodegenerative diseases.
PB Medknow Publications
SN 1673-5374
YR 2020
FD 2020-01-28
LK https://hdl.handle.net/20.500.14352/6028
UL https://hdl.handle.net/20.500.14352/6028
LA eng
NO Date of Submission	07-Oct-2019Date of Decision	21-Oct-2019Date of Acceptance	11-Nov-2019Date of Web Publication	28-Jan-2020
NO Ministerio de Economía y Competitividad de España (MINECO)/Instituto de Salud Carlos III
NO Instituto de Salud Carlos III (ISCIII)/ FEDER
NO Ministerio de Ciencia, Innovación y Universidades (MICINN)
NO Universidad Complutense de Madrid (España)
DS Docta Complutense
RD 29 abr 2024